Summary & Overview
CPT 90587: Quadrivalent Dengue Vaccine, Subcutaneous, Three-Dose
CPT code 90587 denotes a quadrivalent live attenuated dengue vaccine administered subcutaneously in a three–dose series to prevent dengue fever. As dengue risk and vaccine availability remain public health priorities, this immunization code matters nationally for preventive care, travel medicine, and outbreak response planning. Payers and providers use the code to identify vaccine services, track immunization coverage, and process claims for a novel preventive product with a multi-dose schedule.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical service settings, and common billing considerations tied to this vaccine product. The publication outlines expected benchmarks and policy-relevant topics such as payer coverage patterns, administration settings, and coding implications for a three-dose live vaccine series. It also flags where input data is not available for detailed elements such as associated taxonomies, specific ICD-10 diagnoses, or related codes. This national summary is intended to inform billing staff, compliance teams, and policy analysts about the code’s purpose, typical use cases, and areas where organizations may need to seek additional payer-specific guidance.
Billing Code Overview
CPT code 90587 represents a quadrivalent live attenuated dengue vaccine product administered subcutaneously. The vaccine is intended to protect against dengue virus, which causes dengue fever, and is supplied as a three–dose schedule.
-
Service type: Preventive immunization (vaccine administration)
-
Typical site of service: Outpatient clinics, primary care offices, travel medicine clinics, public health vaccination clinics, and other ambulatory care settings where subcutaneous vaccines are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 28-year-old patient traveling to a dengue-endemic region presents to a primary care clinic for immunization counseling. After screening for prior dengue infection and contraindications, the clinician administers the first dose of the quadrivalent live dengue vaccine subcutaneously using a three-dose schedule. Typical workflow: pre-visit vaccine eligibility screening and documentation of prior dengue infection status; informed consent and review of contraindications (e.g., severe allergic reaction to prior vaccine component, immunocompromised status); preparation and subcutaneous administration of the vaccine; observation for immediate adverse reaction (usually 15–30 minutes); documentation in the medical record and immunization registry; scheduling of follow-up doses at recommended intervals. Typical site of service is an outpatient clinic, travel medicine clinic, or public health vaccination center. The service type is vaccine administration (preventive immunization), subcutaneous, for a live, quadrivalent dengue vaccine given as part of a three-dose primary series.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier applicable or not used | Rarely appended; used when no other modifier applies and payer accepts unmodified code |
22 |